Last reviewed · How we verify
TPN171H
TPN171H is a small molecule that targets the SGLT2 receptor.
TPN171H is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | TPN171H |
|---|---|
| Also known as | Simmerafil |
| Sponsor | Vigonvita Life Sciences |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TPN171H reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. TPN171H's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
- Increased risk of increased urination
- Increased risk of dehydration
- Increased risk of hypoglycemia
- Increased risk of increased thirst
- Increased risk of increased urination
- Increased risk of electrolyte imbalance
Key clinical trials
- Long-term Safety of TPN171H Tablet in Erectile Dysfunction. (PHASE3)
- Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension (PHASE2)
- A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects (PHASE1)
- Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects (PHASE1)
- Drug-Drug Interaction (DDI) Study for TPN171H (PHASE1)
- The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension (PHASE1)
- Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction (PHASE2)
- Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPN171H CI brief — competitive landscape report
- TPN171H updates RSS · CI watch RSS
- Vigonvita Life Sciences portfolio CI